Chemomab changes CEOs, suspends mid-stage trial; Ex-FDA vaccine official lends more help to Mesoblast
→ There’s a shakeup at the top of Chemomab Therapeutics as the Israeli biotech halts the start of a Phase II study to save cash …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
